CRYOPORT, INC. Cost, Overhead
CRYOPORT, INC. (CYRX) reported Cost, Overhead of $600.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSoldOverhead · last filed 2026-08-06
- CRYOPORT, INC. cost, overhead for the quarter ending 2026-06-30 was $600.00K, a 14.29% decline year-over-year.
- CRYOPORT, INC. cost, overhead for the quarter ending 2026-03-31 was $600.00K, a 25.00% decline year-over-year.
- CRYOPORT, INC. cost, overhead for the quarter ending 2025-12-31 was $500.00K, a 0.00% change year-over-year.
- CRYOPORT, INC. cost, overhead for the quarter ending 2025-09-30 was $500.00K, a 0.00% change year-over-year.
- CRYOPORT, INC. cost, overhead for fiscal 2025 was $2.50M, a 13.64% increase from fiscal 2024.
- CRYOPORT, INC. cost, overhead for fiscal 2024 was $2.20M, a 0.00% change from fiscal 2023.
- CRYOPORT, INC. cost, overhead for fiscal 2023 was $2.20M.
| Period end | Cost, Overhead 3 month | Cost, Overhead 6 month | Cost, Overhead 9 month | Cost, Overhead 12 month |
|---|---|---|---|---|
| 2026-06-30 | $600.00K 10-Q · filed 2026-08-06 | $1.20M 10-Q · filed 2026-08-06 | $1.70M derived: sum of 3 quarters · filed 2026-08-06 | $2.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $600.00K 10-Q · filed 2026-05-05 | $1.10M derived: sum of 2 quarters · filed 2026-05-05 | $1.60M derived: sum of 3 quarters · filed 2026-05-05 | $2.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.00M derived: sum of 2 quarters · filed 2026-03-05 | $1.70M derived: sum of 3 quarters · filed 2026-08-06 | $2.50M 10-K · filed 2026-03-05 |
| 2025-09-30 | $500.00K 10-Q · filed 2025-11-06 | $1.20M derived: sum of 2 quarters · filed 2026-08-06 | $2.00M 10-Q · filed 2025-11-06 | $2.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $700.00K 10-Q · filed 2026-08-06 | $1.50M 10-Q · filed 2026-08-06 | $2.00M derived: sum of 3 quarters · filed 2026-08-06 | $2.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $800.00K 10-Q · filed 2026-05-05 | $1.30M derived: sum of 2 quarters · filed 2026-05-05 | $1.80M derived: sum of 3 quarters · filed 2026-05-05 | |
| 2024-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.00M derived: sum of 2 quarters · filed 2026-03-05 | $2.20M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $500.00K 10-Q · filed 2025-11-06 | $1.70M 10-Q · filed 2025-11-06 | ||
| 2023-12-31 | $2.20M 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |